Lung-targeting single-domain antibodies and purification methods
| DWPI Title: New single-domain antibody construct is used for targeting to human or mammalian lung tissue for treating, diagnosing, or prophylactically treating disease, e.g., coronavirus, condition, or malignancy, such as cancer, or bacterial infection |
| Abstract: Disclosed herein are single-domain antibodies (sdABs) configured for targeting to human or mammalian lung tissue. Constructs and methods of using such sdABs are also described herein, such as methods of binding with and transporting other sdABs or other cargo with beneficial functionalities, binding to and transporting biochemical or pharmaceutical species with beneficial functionalities, and a method of treating, diagnosing, or prophylactically treating a disease, condition, or malignancy. A purification method for in vivo treatment or testing is also provided. |
| Use: Single-domain antibody construct is used for targeting to human or mammalian lung tissue for treating, diagnosing, or prophylactically treating a disease, e.g., coronavirus, condition, or malignancy, such as cancer, or a bacterial infection. No biological data given. |
| Advantage: The single-domain antibodies are synthetic humanized sdABs developed based on a library, single-domain antibodies are produced as heavy chain only antibodies which are smaller and more modular than conventional antibodies with the ability to engage the immune response. The single-domain antibodies increases therapeutic efficacy by clearing the infection locally, and reducing the likelihood of systemic complications. The qualities and features of single-domain antibodies make tissue-targeted single-domain antibody therapies potentially much more effective than current solutions, and the treatments are easier and cheaper to manufacture. |
| Novelty: Single-domain antibody construct comprising a first single-domain antibody with a binding domain, where the binding domain comprises a first polypeptide comprising first, second, and third complementarity determining regions selected from combination of amino acid sequences containing 7-15 amino acids (SEQ ID NOs: 1, 26, and 51; 2, 27, and 52; 3, 28, and 53; 4, 29, and 54; 5, 30, and 55; 6, 31, and 56; 7, 32, and 57; 8, 33, and 58; 9, 34, and 59; 10, 35, and 60; 11, 36, and 61; 12, 37, and 62; 13, 38, and 63; 14, 39, and 64; 15, 40, and 65; 16, 41, and 66; 17, 42, and 67; 18, 43, and 68; 19, 44, and 69; 20, 45, and 70; 21, 46, and 71; 22, 47, and 72; 23, 48, and 73; 24, 49, and 74; and 25, 50, and 75), respectively, given in the specification, is new. |
| Filed: 9/27/2022 |
| Application Number: US17953930A |
| Tech ID: SD 15930.0 |
| This invention was made with Government support under Contract No. DE-NA0003525 awarded by the United States Department of Energy/National Nuclear Security Administration. The Government has certain rights in the invention. |
| Data from Derwent World Patents Index, provided by Clarivate All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license. |